Skip to main content
< Back to news
Xenopat management team. Photo / Xenopat.
 08.10.2024

Xenopat partners with Inaphaea BioLabs to improve preclinical trials in oncology

Xenopat, based in the Parc Científic de Barcelona and specialising in services focused on the development of personalised oncology treatments from the basic preclinical to post-commercial phases, has entered into a strategic agreement with Inaphaea to incorporate the British company’s extensive biobank into its OrthoXenoBank platform.

The partnership will give Xenopat access to the more than 470 patient-derived cells (PDCs) in the biobank of Inaphaea BioLabs, a subsidiary company of ValiRx Plc. Xenopat will be able to use these PDCs in its Xenograft models and to expand preclinical testing capabilities in the field of oncology.

“Our new partnership with Inaphaea is an important step for the growth of both companies. We look forward to developing new Xenograft models for our customers using Inaphaea’s PDCs, while providing our customer base with earlier-stage, high-throughput in vitro capabilities thanks to Inaphaea’s translational research capabilities,” said Anna Portela, CEO of Xenopat.

“This agreement marks another milestone in the commercialisation of Inaphaea’s PDC bank, expanding the range of in vivo models available for commercial use. Xenopat’s expertise in Xenograft models makes them an ideal partner to further deploy our biobank of over 470 PDCs to their customers, while expanding our commercial reach for in vitro service contracts,” said Mark Eccleston, CEO of ValiRx.

» News post: Xenopat’s LinkedIn [+]